Is it true that Novavax has developed the COVID-19 vaccine which can effectively control corona-virus?
Advances in the development of a corona vaccine have given Novavax a leap in price. The shares of the pharmaceutical company rise by almost 18 percent on Tuesday. The company claims to start testing the vaccine on humans. The titles of rival Moderna, who announced trials of his vaccine candidate for humans last week, lost two percent.
Over 120 different laboratories are trying hard to fast-track COVID-19 vaccine. Pfizer (Germany) announced that a COVID-19 vaccine may be available by 2020 (1-2). The important challenge is production of billions of doses of the vaccine to halt COVID-19 pandemic
1. https://www.webmd.com/lung/news/20200515/pfizer-says-covid-19-vaccine-could-arrive-in-october
2. https://www.cnbc.com/2020/05/12/pfizer-wants-to-expand-human-trials-of-coronavirus-vaccine-to-thousands-of-people-by-september-ceo-says.html
At the moment, there are 10 COVID-19 candidate vaccines in clinical trials, and over 120 in preclinical evaluation. Novavax's candidate vaccine is one of the 10 vaccines currently in clinical trials.
Their vaccine is a protein subunit-based formulation consisting of a stabilized and pre-fusion form of the spike protein. Unlike other technologies such as RNA, DNA, and adenovirus-based vaccines, protein vaccines have been extensively tested in humans as prophylactic treatments for multiple other diseases.
Because we have more data on how these formulations perform in the long-term, Novavax's candidate does have a good chance of being licensed for human use for the prevention of the COVID-19 disease. First clinical data should be available by July.
If you want more information regarding the limitations and strengths of all candidate vaccines in clinical trials, please check this comprehensive article:
https://www.proteogenix.science/scientific-corner/peptide-synthesis/covid-19-candidate-vaccines-in-clinical-trials/
Yes, vaccines were developing antibodies against SARS-CoV-19, but the duration of passive immunity was short-lived.
The reason was that even active immunity after recovery from COVID-19 is short-lived, is not reasonably protective, and is unlikely to prevent reinfections.
So world will need to live with Coronavirus until it itself says goodbye!
To know why and how, read the shocking facts in this latest publication:
https://www.medrxiv.org/content/10.1101/2020.06.13.20130252v1.full.pdf